Summary & Overview
HCPCS Level II Q5129: Bevacizumab-adcd (Vegzelma) Injection, 10 mg
HCPCS Level II code Q5129 designates a 10 mg unit of bevacizumab-adcd (Vegzelma), a biosimilar formulation of the anti-VEGF monoclonal antibody bevacizumab used primarily in oncology and some ophthalmic treatments. The code is important for accurately capturing biosimilar drug utilization and costs across outpatient infusion settings and physician offices, supporting billing consistency as biosimilars expand in clinical use.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national-level overview of how the code is used, what settings it typically applies to, and the clinical context for bevacizumab biosimilar administration. The publication outlines benchmarking elements relevant to payers and providers, summarizes recent policy considerations affecting biosimilar coding and coverage, and clarifies operational points such as service type and typical site of service.
This summary equips billing managers, revenue cycle staff, and policy analysts with concise information on code definition, clinical application, and payer relevance. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code Q5129 represents an injection of bevacizumab-adcd (Vegzelma), biosimilar, 10 mg. This code is used to bill for administration of the specified biosimilar formulation of bevacizumab, an anti-VEGF monoclonal antibody used in oncology and certain ophthalmology indications.
Service Type: Parenteral drug administration (intravenous injection/infusion)
Typical Site of Service: Hospital outpatient infusion center, physician office infusion suite, or ambulatory infusion center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a neovascular ocular or oncologic condition receiving an intravitreal or systemic biosimilar bevacizumab preparation, Q5129 (injection, bevacizumab-adcd (Vegzelma), biosimilar, 10 mg). In ophthalmology, a patient with neovascular age-related macular degeneration (AMD) or diabetic macular edema presents to an ambulatory ophthalmology clinic for intravitreal anti-VEGF therapy. The clinical workflow includes pre-procedure assessment (visual acuity, intraocular pressure, and slit-lamp exam), informed consent, sterile intravitreal injection of the bevacizumab biosimilar, post-injection observation for 15–30 minutes, instructions for signs of infection, and scheduling of follow-up. In oncology or infusion settings, a patient with a solid tumor (e.g., metastatic colorectal cancer) receives an intravenous infusion of bevacizumab biosimilar in an outpatient infusion center; workflow includes chemotherapy order verification, baseline vitals and labs, infusion administration, monitoring for infusion reactions or hypertension, and documentation of lot number and discarded drug (if any). Typical sites of service are an ambulatory ophthalmology clinic or an outpatient infusion center/oncology clinic depending on indication. Common reasons for modifier use include reporting professional/technical components, discontinued services, services not completed as planned, and documenting that unused drug was discarded.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |